title: Treatment of rabbit cheyletiellosis with selamectin or ivermectin: a retrospective case study.
abstract: BACKGROUND
  A retrospective study of rabbits treated against cheyletiellosis was performed to evaluate the efficacy and safety of selamectin or ivermectin in clinical practice.
  
  
  METHODS
  Medical records from 53 rabbits with microscopically confirmed Cheyletiella infestation were collected from two small animal clinics. The rabbits were divided into three groups, based on treatment protocols. Group 1 included 11 rabbits treated with ivermectin injections at 200-476 microg kg-1 subcutaneously 2-3 times, with a mean interval of 11 days. In Group 2, 27 rabbits were treated with a combination of subcutaneous ivermectin injections (range 618-2185 microgkg-1) and oral ivermectin (range 616-2732 microgkg-1) administered by the owners, 3-6 times at 10 days interval. The last group (Group 3) included 15 rabbits treated with selamectin spot-on applications of 6.2-20,0 mgkg-1, 1-3 times with an interval of 2-4 weeks. Follow-up time was 4 months-4.5 years.
  
  
  RESULTS
  Rabbits in remission were 9/11 (81,8%), 14/27 (51,9%) and 12/15 (80,8%) in groups 1, 2 and 3, respectively.
  
  
  CONCLUSIONS
  All treatment protocols seemed to be sufficiently effective and safe for practice use. Though very high doses were used in Group 2 (ivermectin injections followed by oral administration), the protocol seemed less efficacious compared to ivermectin injections (Group 1) and selamectin spot on (Group 3), respectively, although not statistically significant. Controlled prospective studies including larger groups are needed to further evaluate efficacy of the treatment protocols.
authors.affiliation: Djurklinik Stigsbo, Stigsbo 213, Stjärnsund, Sweden. lindstr.mellgr@ebox.tninet.se
authors.forename: Marianne
authors.initials: M
authors.lastname: Mellgren
authors.forename: Kerstin
authors.initials: K
authors.lastname: Bergvall
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000977:Antiparasitic Agents / Q000627:therapeutic use*; D005260:Female; D007279:Injections, Subcutaneous; D007559:Ivermectin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D008297:Male; D008924:Mite Infestations / Q000188:drug therapy / Q000662:veterinary*; D008925:Mites; D011817:Rabbits; D011897:Random Allocation; D012189:Retrospective Studies; D012449:Safety; D016896:Treatment Outcome
chemical_list: D000977:Antiparasitic Agents; D007559:Ivermectin; C414354:selamectin